Abstract
The phosphoinositide 3-kinases (PI3Ks) are lipid kinases that play a central role in control of cell growth, proliferation, migration, survival and angiogenesis, and drive the progression of tumors by activating phosphoinositidedependent kinase, protein kinase B (Akt) and the mammalian target of rapamycin (mTOR). The PI3K/Akt/mTOR pathway has been shown to play an important role in cancer and has become an important target for anticancer drug development. An interest in targeting two important points along this critical signaling pathway has spurred the development of dual PI3K/mTOR inhibitors that could both prevent cancer cell proliferation and induce programmed cell death (apoptosis) by fully suppressing Akt activation. This review summarizes the developments of a diversity of small molecule dual PI3K/mTOR inhibitors in recent 10 years, with an emphasis on their structural features, the relevant biological activities, and the structure-activity relationships (SARs).
Keywords: Anticancer, anticancer agents, cancer, dual PI3K/mTOR kinase inhibitors, kinase inhibitors, PI3K, PI3K, PI3K/Akt/mTOR, PI3K signaling pathway, mTOR, structure-activity relationships, SARs.
Mini-Reviews in Medicinal Chemistry
Title:Recent Developments of Small Molecule PI3K/mTOR Dual Inhibitors
Volume: 13 Issue: 14
Author(s): Yan-Na Liu, Ren-Zhong Wan and Zhao-Peng Liu
Affiliation:
Keywords: Anticancer, anticancer agents, cancer, dual PI3K/mTOR kinase inhibitors, kinase inhibitors, PI3K, PI3K, PI3K/Akt/mTOR, PI3K signaling pathway, mTOR, structure-activity relationships, SARs.
Abstract: The phosphoinositide 3-kinases (PI3Ks) are lipid kinases that play a central role in control of cell growth, proliferation, migration, survival and angiogenesis, and drive the progression of tumors by activating phosphoinositidedependent kinase, protein kinase B (Akt) and the mammalian target of rapamycin (mTOR). The PI3K/Akt/mTOR pathway has been shown to play an important role in cancer and has become an important target for anticancer drug development. An interest in targeting two important points along this critical signaling pathway has spurred the development of dual PI3K/mTOR inhibitors that could both prevent cancer cell proliferation and induce programmed cell death (apoptosis) by fully suppressing Akt activation. This review summarizes the developments of a diversity of small molecule dual PI3K/mTOR inhibitors in recent 10 years, with an emphasis on their structural features, the relevant biological activities, and the structure-activity relationships (SARs).
Export Options
About this article
Cite this article as:
Liu Yan-Na, Wan Ren-Zhong and Liu Zhao-Peng, Recent Developments of Small Molecule PI3K/mTOR Dual Inhibitors, Mini-Reviews in Medicinal Chemistry 2013; 13 (14) . https://dx.doi.org/10.2174/13895575113136660105
DOI https://dx.doi.org/10.2174/13895575113136660105 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Mini Review: Origin, Treatments, Preventions, Real Facts and Viability of the Recent Pandemic of Novel Coronavirus-2019
Coronaviruses Infection, Infectious Agents and Vascular Disease
Reviews on Recent Clinical Trials Structure and Function of the Human Breast Cancer Resistance Protein (BCRP/ABCG2)
Current Drug Metabolism Adipose-Derived Stromal/Stem Cells (ASC) in Regenerative Medicine: Pharmaceutical Applications
Current Pharmaceutical Design Targeting Lipoxygenases (LOs): Drug Design And Discovery
Current Enzyme Inhibition Microwave-Assisted Synthesis of Substituted 2,4-Diarylthiazoles and their Evaluation as Anticancer Agents
Letters in Drug Design & Discovery Significant Breakthroughs in Search for Anti-Infectious Agents Derived from Erythromycin A
Current Medicinal Chemistry New Insights into the Structural Features and Functional Relevance of Human Cytochrome P450 2C9. Part II
Current Drug Metabolism Design, Synthesis and Biological Evaluation of Novel Tetrahydroquinoline Based Propanehydrazides as Antitubercular Agents
Letters in Drug Design & Discovery Editorial [Hot Topic:Structuring Chemical Information for Quicker and More Reliable Drug Safety Assessment (Guest Editor: Romualdo Benigni)]
Current Computer-Aided Drug Design Sarcolemmal K<sub>ATP</sub> Channel Modulators and Cardiac Arrhythmias
Current Medicinal Chemistry Fragment Based Drug Design: From Experimental to Computational Approaches
Current Medicinal Chemistry <i>Chemi-Informatic</i> Approach to Investigate Putative Pharmacoactive Agents of Plant Origin to Eradicate COVID-19
Coronaviruses Recent Advances in the Discovery of Novel Peptide Inhibitors Targeting 26S Proteasome
Anti-Cancer Agents in Medicinal Chemistry Triterpene Derivatives as Inhibitors of Protein Involved in the Inflammatory Process: Molecules Interfering with Phospholipase A2, Cycloxygenase, and Lipoxygenase
Current Drug Targets Potential Role of Hydrogen Sulfide in the Pathogenesis of Vascular Dysfunction in Septic Shock
Current Vascular Pharmacology Selective Divalent Copper Chelation for the Treatment of Diabetes Mellitus
Current Medicinal Chemistry IRAK-4 Inhibitors for Inflammation
Current Topics in Medicinal Chemistry Mathematical Methods to Analysis of Topology, Functional Variability and Evolution of Metabolic Systems Based on Different Decomposition Concepts
Current Drug Metabolism Advances in Discovery of PDE10A Inhibitors for CNS-Related Disorders. Part 1: Overview of the Chemical and Biological Research
Current Drug Targets